Venclexta/Venclyxto combo extends myeloid leukaemia survival
Roche has announced that its Phase III VIALE-A study, evaluating Venclexta/Venclyxto (venetoclax) in combination with azacitidine for acute myeloid leukaemia (AML), ...
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative